Canocapavir

Canocapavir (ZM-H1505R) is a novel, orally active small molecule inhibitor targeting the hepatitis B virus (HBV) core protein. It acts as a capsid assembly modulator with a unique pyrazole structure and binds to a new site on the HBV core protein, distinct from previously reported Type I and Type II HBV core protein allosteric modulators. Canocapavir interferes with the assembly of HBV particles by inducing formation of empty viral capsids devoid of genomic material, thereby inhibiting packaging of pre-genomic RNA into the viral capsid and blocking formation of covalently closed circular DNA (cccDNA). The drug is being developed primarily for chronic hepatitis B infection. Clinical studies have shown that canocapavir significantly reduces serum levels of HBV DNA and pregenomic RNA in treatment-naïve patients with chronic hepatitis B, with good safety and tolerability profiles in early-phase trials[1][4][5][6].

Other names

(S)-Canocapavir